$0.0011
0[0.00%]
Last update: 3:29PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
| Open- | Close- |
| Vol / Avg.0 / 29.412K | Mkt Cap- |
| Day Range- - - | 52 Wk Range0.001 - 0.001 |
Agile Therapeutics Stock (OTC:AGXRW), Key Statistics
Agile Therapeutics Stock (OTC: AGXRW) analysis, key statistics.
Valuation Measures
Enterprise Value
- -
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
- -
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
- -
Tangible Book value per share
- -
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (OTC:AGXRW), Key Statistics
Agile Therapeutics Stock (OTC: AGXRW) analysis, key statistics.
Valuation Measures
Enterprise Value
- -
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
- -
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
- -
Tangible Book value per share
- -
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (OTC:AGXRW), Key Statistics
Agile Therapeutics Stock (OTC: AGXRW) analysis, key statistics.
Valuation Measures
Enterprise Value
- -
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
- -
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
- -
Tangible Book value per share
- -
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (OTC:AGXRW), Key Statistics
Agile Therapeutics Stock (OTC: AGXRW) analysis, key statistics.
Valuation Measures
Enterprise Value
- -
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
- -
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
- -
Tangible Book value per share
- -
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (OTC:AGXRW), Key Statistics
Agile Therapeutics Stock (OTC: AGXRW) analysis, key statistics.
Valuation Measures
Enterprise Value
- -
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
- -
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
- -
Tangible Book value per share
- -
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (OTC:AGXRW), Key Statistics
Agile Therapeutics Stock (OTC: AGXRW) analysis, key statistics.
Valuation Measures
Enterprise Value
- -
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
- -
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
- -
Tangible Book value per share
- -
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (OTC:AGXRW), Key Statistics
Agile Therapeutics Stock (OTC: AGXRW) analysis, key statistics.
Valuation Measures
Enterprise Value
- -
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
- -
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
- -
Tangible Book value per share
- -
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (OTC:AGXRW), Key Statistics
Agile Therapeutics Stock (OTC: AGXRW) analysis, key statistics.
Valuation Measures
Enterprise Value
- -
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
- -
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
- -
Tangible Book value per share
- -
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%